Patents by Inventor Peter Small
Peter Small has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110206715Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb. isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be reintroduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: ApplicationFiled: April 2, 2010Publication date: August 25, 2011Inventors: MARCEL BEHR, PETER SMALL, GARY SCHOOLNIK, MICHAEL A. WILSON
-
Patent number: 7700118Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tubercuosis to attenuate the pathogenic bacteria.Type: GrantFiled: March 14, 2008Date of Patent: April 20, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Publication number: 20080254052Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tubercuosis to attenuate the pathogenic bacteria.Type: ApplicationFiled: March 14, 2008Publication date: October 16, 2008Inventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Patent number: 7364740Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: GrantFiled: June 1, 2005Date of Patent: April 29, 2008Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Publication number: 20060002953Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: ApplicationFiled: June 1, 2005Publication date: January 5, 2006Inventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael Wilson
-
Publication number: 20040063923Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: ApplicationFiled: August 21, 2003Publication date: April 1, 2004Inventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Patent number: 6686166Abstract: Specific genetic deletions are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: GrantFiled: June 27, 2001Date of Patent: February 3, 2004Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Publication number: 20040018574Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tbThe genetic markers can be used for diagnosis of M. tb. infection. One or more antigens provided from the genetic markers can be used in diagnostic assays, e.g. a serological assay.Type: ApplicationFiled: March 14, 2003Publication date: January 29, 2004Inventors: Marcel Behr, Peter Small, Michael A. Wilson, Gary Schoolnik, Claus Aagaard, Ida Rosenkrands, Karin Weldingh, Peter Andersen
-
Publication number: 20020176873Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: ApplicationFiled: June 27, 2001Publication date: November 28, 2002Inventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Patent number: 6291190Abstract: Specific genetic deletions are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: GrantFiled: May 25, 1999Date of Patent: September 18, 2001Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Patent number: 4729883Abstract: The invention relates to a process for the removal of acid gases from gaseous mixtures wherein said mixture is contacted with an aqueous alkaline solution comprising a compound of an alkali metal or ammonia and an alkanolamine-based promoter characterized in that the promoter is a mixture of at least one secondary alkanolamine and at least one N-alkyl-2-aminoethanol, said alkyl radical containing up to 3 carbon atoms.Type: GrantFiled: September 5, 1986Date of Patent: March 8, 1988Assignee: British Gas CorporationInventors: Chi W. Lam, Terence J. Ritter, Peter Small
-
Patent number: 4089826Abstract: The agents comprise a mixture of(A) an adduct of a polyethylenepolyamine or a polypropylenepolyamine with an aliphatic or aromatic diglycidyl ether and(B) an aminoalcohol containing at least two aliphatic amino-hydrogen atoms, especially an adduct of a poly(aminoamide) with certain monoepoxides.(A) has the formula ##STR1## and (B) the formula ##STR2## where R.sup.1 represents a C.sub.2 -C.sub.60 hydrocarbon radical having amino or amido nitrogen in the chain, optionally substituted by amino or alcoholic hydroxy groups, being such that (B) contains at least two aliphatic amino-nitrogen hydrogen atoms,R.sup.2 represents ##STR3## R.sup.3 represents the residue (mol. weight 56 to 5,000) of an at least dihydric alcohol or phenol,P is an integer of average value 1 to 1.5,q is an integer of 1 to 5,R.sup.4 represents a hydrogen atom, C.sub.1 -C.sub.3 alkyl, phenyl, cresyl, chlorophenyl group, or a group R.sup.5 OCH.sub.2 --,R.sup.5 represents a C.sub.1 -C.sub.Type: GrantFiled: October 28, 1975Date of Patent: May 16, 1978Assignee: Ciba-Geigy CorporationInventors: Noel Sydney Moss, Michael Peter Small